US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive, in 2020. It has also been designated as an ...

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s UPLIZNA as the first and only treatment for adults living ...

A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...